Insulin receptor substrate-1 and Golgi phosphoprotein 3 are downstream targets of miR‑126 in esophageal squamous cell carcinoma

Li,Haomiao; Meng,Fanyu; Ma,Jun; Yu,Yongkui; Hua,Xionghuai; Qin,Jianjun; Li,Yin

doi:10.3892/or.2014.3327

Insulin receptor substrate-1 and Golgi phosphoprotein 3 are downstream targets of miR‑126 in esophageal squamous cell carcinoma

Authors:
- Haomiao Li
- Fanyu Meng
- Jun Ma
- Yongkui Yu
- Xionghuai Hua
- Jianjun Qin
- Yin Li
View Affiliations

Affiliations: Department of Thoracic Surgery, The Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, Henan 450008, P.R. China, The Second Affiliated Hospital, Institute of Digestive Diseases, Zhengzhou University, Zhengzhou, Henan 450014, P.R. China
Published online on: July 11, 2014 https://doi.org/10.3892/or.2014.3327
Pages: 1225-1233

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Esophageal squamous cell carcinoma (ESCC) is a common histologic subtype in China. It has been suggested that abnormal expression of microRNAs (miRNAs) is associated with carcinogenesis. We investigated miR-126 expression and its potential targets in ESCC. The expression of miR-126 was detected in cancerous and paired paracancer tissues from 102 patients with ESCC. Target analysis of miR-126 was predicted using online tools. The effect of miR-126 expression on target proteins was assessed using miR-126 mimics or miR-126 inhibitors in ESCC cell lines. In addition, the impact of miR-126 on cell proliferation, apoptosis, migration and invasion was detected in ESCC cell lines. The expression of miR-126 was significantly lower in ESCC tissues, which was associated with tumor differentiation, lymph node metastasis, tumor in-depth and TNM stage. Insulin receptor substrate-1 (IRS-1) and Golgi phosphoprotein 3 (GOLPH3) were overexpressed in ESCC. Overexpression of IRS-1 was associated with cell differentiation, whereas GOLPH3 was related to lymph node metastasis, tumor invasion in-depth and TNM stage in ESCC patients. miR-126 mimics downregulated the expression of IRS-1 and GOLPH3 protein and suppressed the proliferation, migration and invasion of ESCC cells, whereas miR-126 inhibitors led to the opposite results. miR-126 suppressed the proliferation, migration and invasion of ESCC cells, and acted as a tumor suppressor in the carcinogenesis of ESCC. IRS-1 and GOLPH3 are downstream targets of miR-126 at the post-transcriptional level in ESCC.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
3	Mathé EA, Nguyen GH, Bowman ED, et al: MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res. 15:6192–6200. 2009.PubMed/NCBI
4	Song QK, Li J, Jiang HD, He YM, Zhou XQ and Huang CY: Esophageal cancer mortality during 2004–2009 in Yanting County, China. Asian Pac J Cancer Prev. 13:5003–5006. 2012.
5	Fareed KR, Kaye P, Soomro IN, et al: Biomarkers of response to therapy in oesophago-gastric cancer. Gut. 58:127–143. 2009. View Article : Google Scholar : PubMed/NCBI
6	Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
7	Pillai RS: MicroRNA function: multiple mechanisms for a tiny RNA? RNA. 11:1753–1761. 2005. View Article : Google Scholar : PubMed/NCBI
8	Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005. View Article : Google Scholar : PubMed/NCBI
9	Croce CM and Calin GA: miRNAs, cancer, and stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
10	Rosenfeld N, Aharonov R, Meiri E, et al: MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol. 26:462–469. 2008. View Article : Google Scholar : PubMed/NCBI
11	Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009. View Article : Google Scholar : PubMed/NCBI
12	Schmidt M, De Maziere A, Smyczek T, et al: The role of Egfl7 in vascular morphogenesis. Novartis Found Symp. 283:18–28; discussion 28–36, 238–241. 2007. View Article : Google Scholar
13	Schmidt M, Paes K, De Maziere A, et al: EGFL7 regulates the collective migration of endothelial cells by restricting their spatial distribution. Development. 134:2913–2923. 2007. View Article : Google Scholar : PubMed/NCBI
14	Li XM, Wang AM, Zhang J and Yi H: Downregulation of miR-126 expression in colorectal cancer and its clinical significance. Med Oncol. 28:1054–1057. 2011. View Article : Google Scholar : PubMed/NCBI
15	Yang J, Lan H, Huang X, Liu B and Tong Y: MicroRNA-126 inhibits tumor cell growth and its expression level correlates with poor survival in non-small cell lung cancer patients. PLoS One. 7:e429782012. View Article : Google Scholar : PubMed/NCBI
16	Otsubo T, Akiyama Y, Hashimoto Y, Shimada S, Goto K and Yuasa Y: MicroRNA-126 inhibits SOX2 expression and contributes to gastric carcinogenesis. PLoS One. 6:e166172011. View Article : Google Scholar : PubMed/NCBI
17	Sasahira T, Kurihara M, Bhawal UK, et al: Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer. Br J Cancer. 107:700–706. 2012. View Article : Google Scholar : PubMed/NCBI
18	Crawford M, Brawner E, Batte K, et al: MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun. 373:607–612. 2008. View Article : Google Scholar : PubMed/NCBI
19	Ye P, Liu J, He F, Xu W and Yao K: Hypoxia-induced deregulation of miR-126 and its regulative effect on VEGF and MMP-9 expression. Int J Med Sci. 11:17–23. 2014. View Article : Google Scholar : PubMed/NCBI
20	Li N, Li X, Huang S, Shen S and Wang X: miR-126 inhibits colon cancer proliferation and invasion through targeting IRS1, SLC7A5 and TOM1 gene. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 38:809–817. 2013.(In Chinese).
21	Lu YY, Sweredoski MJ, Huss D, Lansford R, Hess S and Tirrell DA: Prometastatic GPCR CD97 is a direct target of tumor suppressor microRNA-126. ACS Chem Biol. 9:334–338. 2014. View Article : Google Scholar : PubMed/NCBI
22	Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428. 2009. View Article : Google Scholar : PubMed/NCBI
23	Zhang Y, Wang Z, Chen M, et al: MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer. Mol Cancer. 11:232012. View Article : Google Scholar : PubMed/NCBI
24	Zhao X, Dou W, He L, et al: MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. Oncogene. 32:1363–1372. 2013. View Article : Google Scholar : PubMed/NCBI
25	Tsuchiya S: The role of microRNA-210 in esophageal squamous cell carcinoma. Yakugaku Zasshi. 132:1069–1073. 2012.(In Japanese).
26	Yang R, Dick M, Marme F, et al: Genetic variants within miR-126 and miR-335 are not associated with breast cancer risk. Breast Cancer Res Treat. 127:549–554. 2011. View Article : Google Scholar : PubMed/NCBI
27	White MF: IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab. 283:E413–E422. 2002. View Article : Google Scholar : PubMed/NCBI
28	Porter HA, Perry A, Kingsley C, Tran NL and Keegan AD: IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumors. Cancer Lett. 338:239–248. 2013. View Article : Google Scholar : PubMed/NCBI
29	Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, deAngelis T and Baserga R: Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem. 282:32582–32590. 2007. View Article : Google Scholar : PubMed/NCBI
30	Yin Y, Yan ZP, Lu NN, et al: Downregulation of miR-145 associated with cancer progression and VEGF transcriptional activation by targeting N-RAS and IRS1. Biochim Biophys Acta. 1829:239–247. 2013. View Article : Google Scholar : PubMed/NCBI
31	Scott KL, Kabbarah O, Liang MC, et al: GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature. 459:1085–1090. 2009. View Article : Google Scholar : PubMed/NCBI
32	Hua X, Yu L, Pan W, et al: Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer. Diagn Pathol. 7:1272012. View Article : Google Scholar : PubMed/NCBI
33	Hu BS, Hu H, Zhu CY, Gu YL and Li JP: Overexpression of GOLPH3 is associated with poor clinical outcome in gastric cancer. Tumour Biol. 34:515–520. 2013. View Article : Google Scholar : PubMed/NCBI
34	Wang JH, Chen XT, Wen ZS, et al: High expression of GOLPH3 in esophageal squamous cell carcinoma correlates with poor prognosis. PLoS One. 7:e456222012. View Article : Google Scholar : PubMed/NCBI
35	Li N, Tang A, Huang S, et al: MiR-126 suppresses colon cancer cell proliferation and invasion via inhibiting RhoA/ROCK signaling pathway. Mol Cell Biochem. 380:107–119. 2013. View Article : Google Scholar : PubMed/NCBI